Surrozen Provides First Quarter 2024 Financial Results and Business Update
Provided By GlobeNewswire
Last update: May 8, 2024
SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan
Preclinical data from ARVO 2024 demonstrate the promise of a Surrozen antibody based Wnt mimetic, to activate targeted cell regeneration in cornea endothelial dystrophies and dry eye disease
Read more at globenewswire.com
